CN116840482A - Early diagnosis system for parkinsonism based on exosome synuclein - Google Patents
Early diagnosis system for parkinsonism based on exosome synuclein Download PDFInfo
- Publication number
- CN116840482A CN116840482A CN202210287557.2A CN202210287557A CN116840482A CN 116840482 A CN116840482 A CN 116840482A CN 202210287557 A CN202210287557 A CN 202210287557A CN 116840482 A CN116840482 A CN 116840482A
- Authority
- CN
- China
- Prior art keywords
- synuclein
- exosomes
- parkinson
- disease
- early diagnosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001808 exosome Anatomy 0.000 title claims abstract description 156
- 238000013399 early diagnosis Methods 0.000 title claims abstract description 50
- 208000027089 Parkinsonian disease Diseases 0.000 title claims abstract description 18
- 206010034010 Parkinsonism Diseases 0.000 title claims abstract description 18
- 102000019355 Synuclein Human genes 0.000 title claims abstract description 7
- 108050006783 Synuclein Proteins 0.000 title claims abstract description 7
- 102000003802 alpha-Synuclein Human genes 0.000 claims abstract description 139
- 108090000185 alpha-Synuclein Proteins 0.000 claims abstract description 139
- 210000002381 plasma Anatomy 0.000 claims abstract description 47
- 210000004369 blood Anatomy 0.000 claims abstract description 35
- 239000008280 blood Substances 0.000 claims abstract description 35
- 238000003745 diagnosis Methods 0.000 claims abstract description 21
- 208000018737 Parkinson disease Diseases 0.000 claims description 94
- 239000003153 chemical reaction reagent Substances 0.000 claims description 47
- 238000001514 detection method Methods 0.000 claims description 40
- 238000000605 extraction Methods 0.000 claims description 25
- 238000002360 preparation method Methods 0.000 claims description 11
- 238000000926 separation method Methods 0.000 claims description 10
- 210000002966 serum Anatomy 0.000 claims description 10
- 208000019116 sleep disease Diseases 0.000 claims description 10
- 238000003018 immunoassay Methods 0.000 claims description 9
- 238000002965 ELISA Methods 0.000 claims description 8
- 210000005259 peripheral blood Anatomy 0.000 claims description 5
- 239000011886 peripheral blood Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000000178 monomer Substances 0.000 claims description 2
- 230000005750 disease progression Effects 0.000 abstract description 14
- 206010061818 Disease progression Diseases 0.000 abstract description 13
- 239000003550 marker Substances 0.000 abstract description 11
- 238000002474 experimental method Methods 0.000 abstract description 4
- 238000000034 method Methods 0.000 description 26
- 239000000090 biomarker Substances 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 239000011324 bead Substances 0.000 description 10
- 102000019009 Neural Cell Adhesion Molecule L1 Human genes 0.000 description 9
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 208000019969 rapid eye movement sleep disease Diseases 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 8
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 8
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 8
- 230000005284 excitation Effects 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 208000020685 sleep-wake disease Diseases 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000031877 prophase Effects 0.000 description 3
- 238000004626 scanning electron microscopy Methods 0.000 description 3
- 238000000528 statistical test Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 102000010660 flotillin Human genes 0.000 description 2
- 108060000864 flotillin Proteins 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 210000001259 mesencephalon Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 241001573498 Compacta Species 0.000 description 1
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 206010061296 Motor dysfunction Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 239000012696 Pd precursors Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 208000025535 REM sleep behavior disease Diseases 0.000 description 1
- ABUBSBSOTTXVPV-UHFFFAOYSA-H [U+6].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O Chemical compound [U+6].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O ABUBSBSOTTXVPV-UHFFFAOYSA-H 0.000 description 1
- -1 acridine ester Chemical class 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2864—Sleep disorders
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The application discloses an early diagnosis system for parkinsonism based on exosome synuclein. In experiments on patients, the application finds that compared with a healthy control group, the alpha-synuclein content in the total exosomes of the blood plasma is slightly increased in RBD patients, is obviously increased in PD patients, and the alpha-synuclein content in the exosomes of the blood plasma central source is obviously increased in RBD and PD, so that the application has early diagnosis value. The alpha-synuclein content in the total exosomes of plasma increases with disease progression, and has value in predicting disease progression. The application achieves the aims of noninvasive, high-efficiency and early diagnosis of the parkinsonism through the blood-derived marker, has important significance for early diagnosis of the parkinsonism, can improve the accuracy of diagnosis, and has certain auxiliary guiding significance for clinical early intervention and reduction of later-stage disability.
Description
Technical Field
The application relates to the field of application of molecular biology technology, in particular to an exosome-based early diagnosis marker for parkinsonism and application thereof.
Background
Parkinson's Disease (PD) is the second most common central nervous system degenerative Disease worldwide, whose central pathological process is misfolded α -synuclein (α -synuclein or simply α -Syn) which causes motor dysfunction in the deposition and degeneration of dopaminergic neurons in the substantia nigra compacta of the midbrain. Current diagnosis of PD is based primarily on the clinician's empirical judgment of clinical symptoms, whereas most patients have more than 50% of their midbrain dopamine neurons lost in diagnosing PD. Therefore, an accurate and effective early prediction system is particularly necessary for preventing PD onset and slowing down disease progression. However, the occult onset of PD makes early diagnosis difficult.
Exosomes are lipid bilayer membrane vesicles secreted by a variety of cells, between 40-100nm in diameter. RNA and abundant proteins are contained in exosomes, and play an important role in the process of intercellular information communication. Research shows that the protein in exosomes is relatively stable in blood, has great potential as a clinical diagnosis marker, and is also a hotspot and a break-through of numerous disease diagnosis researches.
In recent years, it has been found that α -synuclein can be transmitted between cells through exosomes as carriers during the progression of PD, and can be secreted extracellularly. Exosomes secreted by central neurons can enter the blood through the circulatory system and be detected in peripheral blood. This secretory activity begins to occur before the symptoms of PD movement appear. Thus the peripheral blood exosome α -synuclein content is a possible early diagnostic marker for PD.
Rapid eye movement sleep disorder (rapid eye movement sleep behavior disorder, RBD) is widely recognized as a prodromal disease of PD, with 80% of age being likely to be converted to PD. However, the diagnosis of RBD depends on polysomnography, which is time-consuming, laborious and costly, and it is difficult to clinically distinguish it from other sleep problems.
Disclosure of Invention
The application aims to provide an exosome-based early diagnosis marker for parkinsonism, wherein the biomarker is alpha-synuclein, phosphorylated alpha-synuclein and alpha-synuclein oligomer.
It is another object of the application to provide the use of said biomarker for the preparation of a PD early diagnosis kit. The kit comprises a total exosome extraction reagent EXOQ (SBI (System Biosciences)), a central source exosome separation reagent (comprising an antibody affinity magnetic bead, an L1CAM (L1 cell adhesion molecule) antibody and an antibody elution reagent) and an alpha-synuclein detection reagent (comprising an alpha-synuclein antibody, an alpha-synuclein standard, an excitation solution and a luminescence solution). The kit also comprises reagents and consumables such as sample diluent, cleaning liquid and the like used in the experiment.
The kit using the alpha-synuclein as a marker can be used for diagnosis of parkinsonism and parkinsonism precursor phase, diagnosis of fast movement eye sleep disorder, parkinsonism disease progress prediction and other purposes.
The application separates the total exosomes and the central exosomes in human plasma and detects the alpha-synuclein content in the exosomes, so that the diagnosis of PD before clinical symptoms appear is possible.
The application discloses an early diagnosis system for parkinsonism based on exosome synuclein. The system comprises three processes of exosome extraction, detection of alpha-synuclein (alpha-synuclein) in exosome and early diagnosis. Exosome extraction includes extracting total exosomes and central-derived exosomes from a blood sample; the method comprises the steps of (1) detecting alpha-synuclein in exosomes, quantitatively calculating the content of the alpha-synuclein in the exosomes by using an alpha-synuclein antibody and applying a chemiluminescent immunoassay technique, an enzyme-linked immunosorbent assay technique (ELISA) and other immune-related detection methods; early diagnosis is accomplished by comparing the amount of alpha-synuclein in a subject sample to a healthy population, and if the amount of alpha-synuclein is increased, it is indicated to be in the prophase of parkinson's disease. In experiments on patients, it was found that compared with healthy controls, the alpha-synuclein content in the total plasma exosomes was slightly increased in RBD patients, significantly increased in PD patients, and significantly increased in both RBD and PD in central plasma-derived exosomes, with early diagnostic value. The alpha-synuclein content in the total exosomes of plasma increases with disease progression, and has value in predicting disease progression.
Accordingly, in one aspect, the present application provides an exosome synuclein-based early diagnosis system for parkinson's disease, characterized in that early diagnosis of parkinson's disease is achieved by detecting the α -synuclein content in blood-derived exosomes in a sample, using detection reagents including a total exosome extraction reagent, a central-derived exosome separation reagent and an α -synuclein content detection reagent.
In one embodiment, the test sample comprises serum or plasma of the subject.
In another embodiment, the detecting comprises extracting exosomes, the extracted exosomes comprising total exosomes of peripheral blood origin and exosomes of central origin.
In yet another embodiment, detecting comprises detecting alpha-synuclein, phosphorylated alpha-synuclein, and alpha-synuclein oligomers.
In another embodiment, the detection method used for detection includes chemiluminescent immunoassay techniques, enzyme linked immunosorbent assay (ELISA) techniques, and other immune-related detection methods.
In yet another embodiment, the detection reagent used for detection comprises an alpha-synuclein antibody, including monomeric, oligomeric, and phosphorylated antibodies.
In another embodiment, the system of the application is used for early diagnosis of parkinson's disease and/or diagnosis of pre-parkinson's disease, optionally for identifying patients with fast-moving eye sleep disorders and/or high risk populations of parkinson's disease.
In another aspect, the application provides the use of an agent for detecting the content of α -synuclein in exosomes for the preparation of a system for diagnosing early parkinson's disease.
In one embodiment, the diagnosing comprises comparing the α -synuclein content in the subject's sample to a healthy population, and if the α -synuclein content is elevated, indicating that the subject is in a prophase stage of parkinson's disease.
In a further aspect, the application provides the use of an agent for detecting the content of α -synuclein in exosomes for the preparation of a system for identifying patients with fast-moving eye sleep disorders and/or high risk populations of parkinson's disease.
In one embodiment, the reagent for detecting the content of alpha-synuclein in exosomes comprises a total exosome extraction reagent, a centrally derived exosome separation reagent, and an alpha-synuclein content detection reagent.
In another aspect, the application provides a biomarker, wherein the biomarker is selected from the group consisting of alpha-synuclein, phosphorylated alpha-synuclein, and alpha-synuclein oligomers, and the biomarker is used for early diagnosis of parkinson's disease based on exosomes.
In a further aspect, the application provides the use of a biomarker in the manufacture of a kit for early diagnosis of parkinson's disease, wherein the biomarker is selected from the group comprising alpha-synuclein, phosphorylated alpha-synuclein and alpha-synuclein oligomers.
In another aspect, the application provides the use of a biomarker in the manufacture of a diagnostic kit for the prophase of parkinson's disease, wherein the biomarker is selected from the group consisting of alpha-synuclein, phosphorylated alpha-synuclein and alpha-synuclein oligomers.
In yet another aspect, the application provides the use of a biomarker in the manufacture of a diagnostic kit for rapid eye movement sleep disorder, wherein the biomarker is selected from the group consisting of alpha-synuclein, phosphorylated alpha-synuclein, and alpha-synuclein oligomers.
In another aspect, the application provides the use of a biomarker in the preparation of a disease progression prediction kit for parkinson's disease, wherein the biomarker is selected from the group consisting of alpha-synuclein, phosphorylated alpha-synuclein and alpha-synuclein oligomers.
In yet another aspect, the present application provides a method for early diagnosing parkinson's disease, the method comprising the steps of:
(a) Collecting a blood sample from a subject suspected of having a rapid eye movement sleep disorder, optionally the collected blood sample being plasma, serum;
(b) Extracting exosomes from the collected blood sample;
(c) Isolating central-derived exosomes from the collected blood sample;
(d) Detecting the α -synuclein content in the exosomes in steps (b) and (c), calculating the protein expression value of α -synuclein;
(e) Comparing the protein expression value obtained with the protein expression value of alpha-synuclein of a healthy subject, if the alpha-synuclein expression is elevated, it is indicative that the subject suffers from a rapid ocular movement sleep disorder and is at high risk for parkinson's disease.
In another aspect, the application provides a method of monitoring disease progression in a subject, the method comprising the steps of:
(a) Collecting blood samples from a subject at different time points, said subject suffering from a rapid eye movement sleep disorder, optionally, the collected blood samples being plasma, serum;
(b) Extracting exosomes from the collected blood sample;
(c) Isolating central-derived exosomes from the collected blood sample;
(d) Detecting the α -synuclein content in the exosomes in steps (b) and (c), calculating an α -synuclein protein expression value;
(e) If the α -synuclein content is increased in samples collected at a later time point than in samples collected at an earlier time point, it is indicative of progression of the disease from a rapid eye movement sleep disorder to Parkinson's disease.
The application achieves the aims of noninvasive, high-efficiency and early diagnosis of the parkinsonism through the blood-derived marker, has important significance for early diagnosis of the parkinsonism, can improve the accuracy of diagnosis, and has certain auxiliary guiding significance for clinical early intervention and reduction of later-stage disability.
Compared with the prior art, the application has the following advantages:
1. the exosome protein alpha-synuclein is used as a marker for early diagnosis of PD, has high sensitivity (0.750) and high specificity (0.688), has the area under ROC curve of 0.741, and provides a brand-new approach for early diagnosis and/or treatment of PD.
2. The application focuses on the diagnosis of PD in the precursor stage, discovers that the alpha-synuclein of the exosome of central origin rises in a long time before the onset of PD, can advance the diagnosis of PD to the RBD stage, provides good basis for early diagnosis and treatment, can be used as early screening and progress prediction index of PD, and can be well applied to clinic.
The application establishes a method for extracting total exosomes and central source exosomes in the blood plasma of PD patients, RBD patients and healthy people and detecting the content of alpha-synuclein in the blood plasma, and provides an early PD (RBD) diagnosis biomarker and application thereof.
The application mainly enriches total exosomes and central-source exosomes in blood, detects the content of alpha-synuclein by a chemiluminescent immunoassay technology, determines the measured analyte value by a test group and performs clinical application in the test group, thereby providing effective auxiliary diagnosis reference for doctors.
The biomarker is alpha-synuclein, including phosphorylated alpha-synuclein and alpha-synuclein oligomer. Preferably, the blood sample used is serum or plasma. The application provides an application of an early PD diagnosis biomarker based on blood exosomes, wherein the detection method of the biomarker is a chemiluminescent immunoassay technology, an enzyme-linked immunosorbent assay (ELISA) technology and other immune-related detection methods. The PD early diagnosis kit mainly comprises exosome extraction, central source exosome separation and alpha-synuclein detection related reagents. Wherein, the PD early diagnosis kit contains an exosome extraction reagent which is EXOQ of SBI company. The PD early diagnosis kit contains a central source exosome separation reagent, wherein the reagent is an L1CAM antibody and magnetic beads (Dynabeads, invitrogen). The PD early diagnosis kit contains an alpha-synuclein detection reagent, wherein the reagent is an alpha-synuclein antibody marked by biotin and acridinium ester and a chemiluminescent excitation liquid.
The foregoing is only a preferred embodiment of the present application. It should be noted that modifications and additions to the application may be made by those skilled in the art without departing from the principles of the application and are considered to be within the scope of the application.
Drawings
FIG. 1 shows the identification of exosomes, (a) Western blot of plasma exosome marker Alix, flotillin; (b) Western blot results of Alix and L1CAM by anti-L1 CAM capture, or normal mouse IgG capture; (c) detecting the concentration and particle size of exosomes; (d) observing the exosome morphology by using an electron microscope.
FIG. 2 shows ROC plots of alpha-synuclein content and diagnostic effect in plasma total exosomes and in central-derived exosomes. (a) Comparison of plasma total exosome alpha-synuclein content in PD, RBD and healthy controls. (b) Comparison of plasma central derived exosome alpha-synuclein content in PD, RBD and healthy controls. (c) ROC diagram of diagnosis of PD by α -synuclein in plasma central derived exosomes. (d) ROC diagram of plasma central derived exosomes diagnostic RBD.
Detailed Description
The application will now be described in detail with reference to the drawings and specific examples. It should be noted that variations and modifications could be made by those skilled in the art without departing from the inventive concept. Such equivalents are also intended to fall within the scope of the application as defined by the following claims. It should be noted that the illustrations provided in the following examples merely illustrate the basic idea of the present application by way of illustration, and it should be understood that these examples are only for illustrating the present application and are not intended to limit the scope of the present application.
Examples
Example 1 preparation of Total exosomes and of central origin exosomes.
This example relates to the preparation of total exosomes and exosomes of central origin.
1.1 extraction of total plasma exosomes
1.1.1 the plasma of the subjects was diluted 1:1 with DPBS (E607009, sangon Biotech) and mixed well.
1.1.2 according to EXOQ reagent (EXOQ 20A-1, SBI) instructions, 500. Mu.l of diluted plasma are taken, 63. Mu.l of EXOQ reagent are added, gently mixed and left to stand.
1.1.3 centrifugation to obtain exosome pellet, and resuspension was performed using 200. Mu.l DPBS or 200. Mu.l RIPA lysate (FD 009, friedel-crafts) to obtain the sample to be tested.
1.2 extraction of Central plasma derived exosomes
1.2.1A 300. Mu.l DPBS was added to 900. Mu.l of the subject's plasma for dilution.
1.2.2L 1CAM antibody (Huabaio ET 1703-51) was mixed well with diluted plasma and 0.25mg IgG affinity beads (Dynabeads, invitrogen) were added overnight at 4 ℃.
1.2.3 washing exosomes and antibodies with RIPA or DPBS, heating at 100 ℃ for 10 min to obtain the sample to be detected.
1.3 exosome identification.
1.3.1 exosomes extracted were fixed with 2% tissue fixative, stained with uranium acetate and observed for exosome morphology at 100kV using transmission electron microscopy.
1.3.2 the extracted exosomes were lysed using RIPA and the exosome markers Alix and florilin and the central source exosome marker L1CAM were identified by protein electrophoresis.
1.3.3 extracted exosomes were subjected to concentration particle detection using a Zetaview nanoparticle tracking analyzer.
FIG. 1 shows the identification of the exosomes of the present application, wherein (a) the plasma exosome marker Alix, flotillin is western-blotted; (b) Western blot results of Alix and L1CAM by anti-L1 CAM capture, or normal mouse IgG capture; (c) detecting the concentration and particle size of exosomes; (d) observing the exosome morphology by using an electron microscope.
Example 2 kit composition
The kit comprises: plasma total exosome extraction reagent: EXOQ (SBI), DPBS, RIPA lysate. Plasma central-derived exosome extraction reagent: l1CAM antibody, DPBS, antibody affinity beads. Alpha-synuclein detection reagent: the kit comprises a labeled alpha-synuclein antibody, an alpha-synuclein protein standard substance, igG affinity magnetic beads, a luminescent pre-excitation solution and excitation solution, and a magnetic bead cleaning solution. The kit should also contain conventional consumables used during the procedure.
Illustratively, the present application provides a kit consisting of:
EXOQ (SBI), DPBS (E607009, sangon Biotech), RIPA lysate (FD 009, friedel biology), protease inhibitor cocktail (FD 1001, friedel biology), L1CAM antibody (Huabio ET 1703-51), igG affinity beads (Dynabeads, invitrogen), DPBS (E607009, sangon Biotech), biotin-labeled α -synuclein antibody, acridine ester-labeled α -synuclein antibody, α -synuclein protein standard (12093-HNAE, sino biology), BSA (a 600332, sangon Biotech), pre-challenge (0.2% hydrogen peroxide as a major component), challenge (0.35M sodium hydroxide as a major component), bead wash buffer, tween-20 (a 100777, sangon Biotech).
Example 3 experiment of application of kit
The application provides assistance for clinical diagnosis and early screening of PD by separating plasma exosomes and plasma central source exosomes of PD patients, RBD patients and healthy controls matched with the patients in age and detecting the alpha-synuclein content in the plasma exosomes. The method specifically comprises the following steps:
3.1 clinical sample collection
54 PD patients, 149 RBD patients, and 55 healthy controls were collected from 2019 to date diagnosed with standard procedure (SOP) at a second hospital affiliated with university of Zhejiang, and corresponding case data (including age, time of onset, motor symptom score, non-motor symptom score, etc.) were collected and collated. The sample quality problem was then eliminated to the PD patient 44, the RBD patient 101, and the healthy control 48.
The subjects collected met the following conditions: (1) clinically definite cases of new PD and RBD; (2) Exclusion of family history, brain trauma history, brain tumor history and other serious systemic diseases; (3) the control was healthy people who were age-matched to the patient.
3.2 exosome protein extraction
3.2.1 extraction of the subject's plasma Total exosomes Using the EXOQ (SBI) reagent
3.2.2 collection of plasma Central derived exosomes Using the immunocomplex method with L1CAM antibodies
3.2.3 extraction of exosome Total protein Using RIPA lysate
3.3 detection of exosome alpha-synuclein content by chemiluminescent immunoassay technique.
3.3.1A standard solution was prepared with a gradient of 32ng/ml, 16ng/ml, 8ng/ml, 4ng/ml, 2ng/ml, 1ng/ml, 0.5ng/ml, 0.25ng/ml, 0.125 ng/ml.
3.3.2 incubating protein standards and samples to be tested with biotin-tagged α -synuclein antibodies, acridine ester-tagged α -synuclein antibodies, and IgG affinity magnetic beads, respectively.
And 3.3.3, eluting the proteins on the magnetic beads, respectively adding a pre-excitation liquid and an excitation liquid into the eluent, and detecting the luminescence value of the sample.
And 3.3.4, drawing a standard curve according to the luminous value of the protein standard substance, and calculating the concentration of the sample to be detected according to a standard curve formula and the luminous value of the sample to be detected.
3.4 data analysis: all statistical tests were performed using GraphPad Prism software 8 (san diego, CA). Data are expressed as mean ± SEMs. P <0.05 is statistically significant for the differences.
3.5 analysis of results
As shown in fig. 2a, the α -synuclein content in the total plasma exosomes was slightly elevated in RBD patients and significantly elevated in PD patients compared to healthy control groups. As shown in the blue curve of fig. 2c, the α -synuclein diagnostic PD in the total plasma exosomes has high sensitivity (0.750) and high specificity (0.688), the area under ROC curve is 0.741. As shown in fig. 2b, the α -synuclein content in plasma central-derived exosomes was significantly elevated in both RBD and PD compared to healthy control, with early diagnostic value. As shown in the green curve of FIG. 2c, the area under the ROC curve for the diagnosis of PD by alpha-synuclein in plasma central-derived exosomes was 0.761. The alpha-synuclein content in the plasma total exosomes increases with disease progression, with value in predicting disease progression (see figure 2 a).
Example 4 early diagnosis of PD
The present application provides a method for early diagnosis of PD, the method comprising the steps of: (a) Collecting a blood sample of the subject, wherein the collected blood sample is blood plasma or blood serum. (b) extracting exosomes from the collected blood sample. (c) Separating the central derived exosomes from the collected blood sample. (d) Detecting the content of alpha-synuclein in the exosomes in the steps (b) and (c), and calculating the alpha-synuclein protein expression value. (e) Comparing the resulting protein expression value to the value of the selected analyte of interest in a healthy subject, if the α -synuclein expression is increased, it is indicative that the subject has RBD and is at high risk for PD.
4.1 Experimental sample collection
149 RBD patients screened since 2019 were collected, 55 healthy controls were collected, and corresponding case data (including age, time of onset, motor symptom score, non-motor symptom score, etc.) were collected and collated. The sample quality problem was then eliminated to the RBD patient 101 and the healthy control 48.
The subjects collected met the following conditions: (1) clinically definite new RBD cases; (2) Exclusion of family history, brain trauma history, brain tumor history and other serious systemic diseases; (3) the control was healthy people who were age-matched to the patient.
4.2 extraction of Central derived exosome proteins
4.2.1 collection of plasma Central derived exosomes Using the immunocomplex method with L1CAM antibodies
4.2.2 extraction of exosome Total protein Using RIPA lysate
4.3 detection of exosome alpha-synuclein content by chemiluminescent immunoassay technique.
4.4 data analysis: all statistical tests were performed using GraphPad Prism software 8 (san diego, CA). Data are expressed as mean ± SEMs. P <0.05 is statistically significant for the differences.
4.5 analysis of results
As shown in FIG. 2b, the α -synuclein content in the central-derived exosomes of RBD patients was significantly elevated compared to healthy controls. As shown in FIG. 2d, the area under the ROC curve for the diagnosis of RBD by alpha-synuclein in the central derived exosomes was 0.727. The above data illustrate that the α -synuclein content in central derived exosomes can be diagnosed during PD precursor phase.
EXAMPLE 5 monitoring disease progression
The present application also provides a method of monitoring disease progression comprising the steps of: (a) The blood samples of the subjects are collected at different time points, and the collected blood samples are blood plasma and blood serum. (b) extracting exosomes from the collected blood sample. (c) Separating the central derived exosomes from the collected blood sample. (d) Detecting the content of alpha-synuclein in the exosomes in the steps (b) and (c), and calculating the alpha-synuclein expression value. (e) Detecting the amount of α -synuclein in the sample collected at a later time point, wherein an increase in the amount of α -synuclein in the sample collected at the later time point compared to the amount in the sample collected at the earlier time point indicates that the disease in the subject progresses from RBD to PD.
5.1 Experimental sample collection
54 PD patients diagnosed by standard procedure (SOP) from 2019 to date at a second hospital affiliated with university of Zhejiang were collected, 55 healthy controls were collected, and corresponding case data (including age, time of onset, motor symptoms score, non-motor symptoms score, etc.) were collected and collated. The samples were then excluded from the PD patients 44 and healthy controls 48 due to sample quality issues.
The subjects collected met the following conditions: (1) clinically definite new PD cases; (2) Exclusion of family history, brain trauma history, brain tumor history and other serious systemic diseases; (3) the control was healthy people who were age-matched to the patient.
4.2 extraction of plasma Total exosome proteins
4.2.1 extraction of plasma exosomes Using the EXOQ kit
4.2.2 extraction of exosome Total protein Using RIPA lysate
4.3 detection of exosome alpha-synuclein content by chemiluminescent immunoassay technique.
4.4 data analysis: all statistical tests were performed using GraphPad Prism software 8 (san diego, CA). Data are expressed as mean ± SEMs. P <0.05 is statistically significant for the differences.
4.5 analysis of results
As a result, it was found that the α -synuclein content was positively correlated with the UPDRS III score of the unified parkinsonism rating scale (p=0.0041). This suggests that the α -synuclein content in exosomes has value in detecting disease progression.
It should be noted that the above embodiments are only for illustrating the technical solution of the present application, and not for limiting the same. Although the application has been described in detail with reference to the preferred embodiments, it will be understood by those skilled in the art that modifications and equivalents may be made thereto without departing from the spirit and scope of the application, which is intended to be covered by the appended claims.
The application includes the following embodiments:
1. an early diagnosis system of parkinsonism based on exosome synuclein is characterized in that early diagnosis of parkinsonism is realized by detecting the content of alpha-synuclein in blood-derived exosomes in a sample, and the detection reagents used comprise a total exosome extraction reagent, a central-derived exosome separation reagent and an alpha-synuclein content detection reagent.
2. The early diagnosis system for parkinson's disease according to embodiment 1, wherein the sample detected comprises serum or plasma of the subject.
3. The early diagnosis system for parkinson's disease according to embodiment 1 or 2, wherein said detection comprises extraction of exosomes, said extracted exosomes comprising total exosomes of peripheral blood origin and exosomes of central origin.
4. The early diagnosis system for parkinson's disease according to embodiment 1 or 2, wherein said detection comprises detection of α -synuclein, phosphorylated α -synuclein and α -synuclein oligomers.
5. The early diagnosis system for parkinson's disease according to embodiment 1 or 2, wherein said detection method comprises chemiluminescent immunoassay, enzyme linked immunosorbent assay and other immune-related detection methods.
6. The early diagnosis system for parkinson's disease according to embodiment 1 or 2, wherein said detection reagent used for said detection comprises an α -synuclein antibody, said α -synuclein comprising a monomer, an oligomer and a phosphorylated antibody.
7. The early diagnosis system for parkinson's disease according to embodiment 1 or 2, characterized in that it is used for early diagnosis of parkinson's disease and/or diagnosis of pre-parkinson's disease, or it is used for identifying patients with fast-moving eye sleep disorder and/or high risk population of parkinson's disease.
8. Use of an agent for detecting the content of α -synuclein in exosomes for the preparation of a system for diagnosing early parkinson's disease or for the preparation of a system for identifying patients with fast-moving eye sleep disorders and/or high risk populations of parkinson's disease.
9. The use of embodiment 8, wherein the use of the kit comprises comparing the α -synuclein content in the subject's sample to a healthy population, and indicating that the subject is in a pre-parkinson's disease stage if the α -synuclein content is elevated.
10. The use according to embodiment 8 or 9, wherein the reagent for detecting the content of α -synuclein in exosomes comprises a total exosome extraction reagent, a centrally-derived exosome separation reagent, and an α -synuclein content detection reagent.
11. A biomarker, wherein the biomarker is selected from the group consisting of alpha-synuclein, phosphorylated alpha-synuclein, and alpha-synuclein oligomers, and the biomarker is used for early diagnosis of parkinson's disease based on exosomes.
12. Use of a biomarker in the preparation of a parkinson's disease early diagnosis kit, a parkinson's disease pre-stage diagnosis kit, a rapid eye movement sleep disorder diagnosis kit, or a parkinson's disease progression prediction kit, wherein the biomarker is selected from the group consisting of alpha-synuclein, phosphorylated alpha-synuclein, and alpha-synuclein oligomers.
13. The use according to embodiment 12, wherein the kit comprises a total exosome extraction reagent, a central-derived exosome separation reagent, and an alpha-synuclein content detection reagent.
14. A method for early diagnosis of parkinson's disease, the method comprising the steps of:
(a) Collecting a blood sample from a subject suspected of having a rapid eye movement sleep disorder, optionally the collected blood sample being plasma, serum;
(b) Extracting exosomes from the collected blood sample;
(c) Isolating central-derived exosomes from the collected blood sample;
(d) Detecting the α -synuclein content in the exosomes in steps (b) and (c), calculating the protein expression value of α -synuclein;
(e) Comparing the protein expression value obtained with the protein expression value of alpha-synuclein of a healthy subject, if the alpha-synuclein expression is elevated, it is indicative that the subject suffers from a rapid ocular movement sleep disorder and is at high risk for parkinson's disease.
15. A method of monitoring disease progression in a subject, the method comprising the steps of:
(a) Collecting blood samples from a subject at different time points, said subject suffering from a rapid eye movement sleep disorder, optionally, the collected blood samples being plasma, serum;
(b) Extracting exosomes from the collected blood sample;
(c) Isolating central-derived exosomes from the collected blood sample;
(d) Detecting the α -synuclein content in the exosomes in steps (b) and (c), calculating an α -synuclein protein expression value;
(e) If the α -synuclein content is increased in samples collected at a later time point than in samples collected at an earlier time point, it is indicative of progression of the disease from a rapid eye movement sleep disorder to Parkinson's disease.
Claims (10)
1. An early diagnosis system of parkinsonism based on exosome synuclein is characterized in that early diagnosis of parkinsonism is realized by detecting the content of alpha-synuclein in blood-derived exosomes in a sample, and the detection reagents used comprise a total exosome extraction reagent, a central-derived exosome separation reagent and an alpha-synuclein content detection reagent.
2. The early diagnosis system of parkinson's disease according to claim 1, wherein the sample tested comprises serum or plasma of the subject.
3. The early diagnosis system of parkinson's disease according to claim 1 or 2, wherein said detection comprises extraction of exosomes, said extracted exosomes comprising total exosomes of peripheral blood origin and exosomes of central origin.
4. The early diagnosis system of parkinson's disease according to claim 1 or 2, wherein said detection comprises detection of α -synuclein, phosphorylated α -synuclein and α -synuclein oligomers.
5. An early diagnosis system for parkinson's disease according to claim 1 or 2, wherein said detection method comprises chemiluminescent immunoassay, enzyme linked immunosorbent assay and other immune related detection methods.
6. The early diagnosis system for parkinson's disease according to claim 1 or 2, wherein said detection reagent used comprises an α -synuclein antibody, said α -synuclein comprising monomers, oligomers and phosphorylated antibodies.
7. The parkinson's disease early diagnosis system according to claim 1 or 2, characterized in that it is used for parkinson's disease early diagnosis and/or parkinson's disease pre-stage diagnosis, or it is used for identifying patients with fast-moving eye sleep disorders and/or high risk population of parkinson's disease.
8. Use of an agent for detecting the content of α -synuclein in exosomes for the preparation of a system for diagnosing early parkinson's disease or for the preparation of a system for identifying patients with fast-moving eye sleep disorders and/or high risk populations of parkinson's disease.
9. The use of claim 8, wherein the use of the kit comprises comparing the α -synuclein content in the subject's sample to a healthy population, and indicating that the subject is in a pre-parkinson's disease stage if the α -synuclein content is elevated.
10. The use according to claim 8 or 9, wherein the reagent for detecting the α -synuclein content in exosomes comprises a total exosome extraction reagent, a centrally derived exosome separation reagent and an α -synuclein content detection reagent.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210287557.2A CN116840482A (en) | 2022-03-23 | 2022-03-23 | Early diagnosis system for parkinsonism based on exosome synuclein |
| PCT/CN2022/138681 WO2023179112A1 (en) | 2022-03-23 | 2022-12-13 | Early-diagnosis system of parkinson's disease based on exosomal synuclein |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210287557.2A CN116840482A (en) | 2022-03-23 | 2022-03-23 | Early diagnosis system for parkinsonism based on exosome synuclein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116840482A true CN116840482A (en) | 2023-10-03 |
Family
ID=88099775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210287557.2A Pending CN116840482A (en) | 2022-03-23 | 2022-03-23 | Early diagnosis system for parkinsonism based on exosome synuclein |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN116840482A (en) |
| WO (1) | WO2023179112A1 (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3161482B1 (en) * | 2014-06-27 | 2020-08-26 | XY Evergreen Technology Company | Method for enriching cns-derived exosomes |
| US10203342B2 (en) * | 2015-06-11 | 2019-02-12 | Nanosomix, Inc. | Biomarkers and differential diagnosis of alzheimer's disease and other neurodegenerative disorders |
| US20190170771A1 (en) * | 2016-07-28 | 2019-06-06 | Lysosomal And Rare Disorders Research And Treatment Center, Llc. | Alpha-synuclein in peripheral blood mononuclear cells as biomarker for synucleinopathy |
| EP3963047A4 (en) * | 2019-04-30 | 2023-06-21 | Chase Therapeutics Corporation | Alpha-synuclein assays |
| US20220390470A1 (en) * | 2019-11-11 | 2022-12-08 | Oxford University Innovation Limited | Biomarkers for the prediction and identification of parkinson's disease |
| CN111537738A (en) * | 2020-05-18 | 2020-08-14 | 南通大学附属医院 | Kit for detecting early Parkinson's disease |
-
2022
- 2022-03-23 CN CN202210287557.2A patent/CN116840482A/en active Pending
- 2022-12-13 WO PCT/CN2022/138681 patent/WO2023179112A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023179112A1 (en) | 2023-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230393133A1 (en) | Blood biomarker that predicts persistent cognitive dysfunction after concussion | |
| WO2010063009A1 (en) | Methods of detecting a neurological condition via analysis of circulating phagocytes | |
| JP2009500641A (en) | Diagnostic method for multiple sclerosis | |
| CN109655608B (en) | Exosome protein for osteosarcoma diagnosis and instant detection method thereof | |
| US20220162272A1 (en) | Compositions and methods of determining a level of infection in a subject | |
| CN112462058A (en) | Circulating nerve cell detection kit and detection method | |
| CN116519953A (en) | Application of EDA2R protein and specific antibody thereof in preparation of syphilis diagnosis product | |
| WO2021039941A1 (en) | Method for determining alzheimer-type dementia or mild cognitive impairment | |
| JPWO2012049874A1 (en) | Biomarker for diagnosing fatty liver disease, measuring method thereof, computer program, and storage medium | |
| EP2451466B1 (en) | Apolipoprotein ciii in pre- and type 2 diabetes | |
| KR102010655B1 (en) | A novel protein marker for diagnosing Alzheimer's disease and the use thereof | |
| JP6128631B2 (en) | Marker for distinguishing diabetic nephropathy and use thereof | |
| CN116840482A (en) | Early diagnosis system for parkinsonism based on exosome synuclein | |
| WO2019012671A1 (en) | Biomarker for cognitive impairment disorders and detection method for cognitive impairment disorders using said biomarker | |
| EP3816628A1 (en) | Pancreatic cancer determination marker | |
| Huang et al. | Proteomic patterns as biomarkers for the early detection of schistosomiasis japonica in a rabbit model | |
| CN113832223A (en) | Hypertension serum extracellular vesicle protein marker and application thereof | |
| WO2019012667A1 (en) | Biomarker for cognitive impairment disorders and detection method for cognitive impairment disorders using said biomarker | |
| CN110850096B (en) | Biomarker group and application thereof, protein chip kit and ELISA kit | |
| WO2015083791A1 (en) | Method for detecting lung cancer and detection kit | |
| CN112180007A (en) | Metabolics-based diagnostic marker for generalized pustular psoriasis and application thereof | |
| CN114609270B (en) | Use of serum lauroyl carnitine as diagnostic marker of asthma | |
| EP4257601A1 (en) | Breast cancer diagnosis assistance method and breast cancer test kit | |
| CN116338191A (en) | Lung cancer exosome protein marker based on flow technology and application thereof in aspect of lung cancer screening | |
| JP2023154548A (en) | Inspection method for ovarian cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |